Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer

被引:127
作者
Tallman, MS
Gray, R
Robert, NJ
LeMaistre, CF
Osborne, CK
Vaughan, WP
Gradishar, WJ
Pisansky, TM
Fetting, J
Paietta, E
Lazarus, HM
机构
[1] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Chicago, IL 60611 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Inova Fairfax Hosp, Falls Church, VA USA
[4] Texas Transplant Inst, San Antonio, TX USA
[5] Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA
[6] Methodist Hosp, Houston, TX 77030 USA
[7] Univ Alabama Birmingham, Birmingham, AL USA
[8] Mayo Clin, Div Radiat Oncol, Rochester, MN USA
[9] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[10] New York Med Coll, Our Lady Mercy Canc Ctr, Bronx, NY USA
[11] Case Western Reserve Univ, Sch Med, Ireland Canc Ctr, Cleveland, OH USA
关键词
D O I
10.1056/NEJMoa030684
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The prognosis for women with primary breast cancer and 10 or more involved axillary lymph nodes is poor. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation has been reported to be effective in the adjuvant setting for patients at high risk for relapse. METHODS: We randomly assigned 540 female patients with primary breast cancer and at least 10 involved ipsilateral axillary lymph nodes to receive either six cycles of adjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil (CAF) or the same adjuvant chemotherapy followed by high-dose chemotherapy with cyclophosphamide and thiotepa and autologous hematopoietic stem-cell transplantation. RESULTS: Among the 511 eligible patients, there was no significant difference in disease-free survival, overall survival, or the time to recurrence between those who received CAF alone and those who received CAF plus high-dose chemotherapy and stem-cell transplantation. Among 417 patients fulfilling strict eligibility criteria, the time to recurrence was longer for patients who underwent stem-cell transplantation than for those who received CAF alone. In the transplantation group, nine patients died of transplantation-related complications and a myelodysplastic syndrome or acute myeloid leukemia developed in nine. CONCLUSIONS: The addition of high-dose chemotherapy and autologous hematopoietic stem-cell transplantation to six cycles of adjuvant chemotherapy with CAF may reduce the risk of relapse but does not improve the outcome among patients with primary breast cancer and at least 10 involved axillary lymph nodes. Conventional-dose adjuvant chemotherapy remains the standard of care for such patients.
引用
收藏
页码:17 / 26
页数:10
相关论文
共 38 条
  • [1] Abruzzese E, 1999, BLOOD, V94, P1814
  • [2] Therapy-related leukemia and myelodysplastic syndrome in breast cancer patients treated with cyclophosphamide or anthracyclines
    Ando, M
    Narabayashi, M
    Watanabe, T
    Kamiya, Y
    Togitani, K
    Tanosaki, R
    Takenaka, T
    Tobinai, K
    Adachi, I
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1999, 29 (01) : 28 - 32
  • [3] High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America
    Antman, KH
    Rowlings, PA
    Vaughan, WP
    Pelz, CJ
    Fay, JW
    Fields, KK
    Freytes, CO
    Gale, RP
    Hillner, BE
    Holland, HK
    Kennedy, MJ
    Klein, JP
    Lazarus, HM
    McCarthy, PL
    Saez, R
    Spitzer, G
    Stadtmauer, EA
    Williams, SF
    Wolff, S
    Sobocinski, KA
    Armitage, JO
    Horowitz, MM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) : 1870 - 1879
  • [4] ADJUVANT SYSTEMIC THERAPY FOR RESECTABLE BREAST-CANCER
    BONADONNA, G
    VALAGUSSA, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (02) : 259 - 275
  • [5] BULL JM, 1978, CANCER, V41, P1649, DOI 10.1002/1097-0142(197805)41:5<1649::AID-CNCR2820410501>3.0.CO
  • [6] 2-J
  • [7] ADJUVANT CHEMOTHERAPY WITH DOXORUBICIN PLUS CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN THE TREATMENT OF RESECTABLE BREAST-CANCER WITH MORE THAN 3 POSITIVE AXILLARY NODES
    BUZZONI, R
    BONADONNA, G
    VALAGUSSA, P
    ZAMBETTI, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (12) : 2134 - 2140
  • [8] Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: A population-based study
    Chaplain, G
    Milan, C
    Sgro, C
    Carli, PM
    Bonithon-Kopp, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (15) : 2836 - 2842
  • [9] COX DR, 1972, J R STAT SOC B, V34, P187
  • [10] CROWN JP, 2002, P AN M AM SOC CLIN, V21, pA42